Abivax Stock Crosses the 100 Euro Mark at Midday, Up 3.31%
This Thursday, November 20, at midday, the French biotech company Abivax has reached a price of 100 euros, marking a 3.31% increase from the previous day. The stock continues its remarkable trajectory since the start of the year with a performance exceeding 1,000%.
Midday Market Update
At mid-session this Thursday, Abivax's stock, which closed at 96.80 euros the previous day, has risen by 3.31% to reach 100 euros. However, trading volumes remain limited with only 0.03% of the capital traded, indicating a tight float. This increase is part of a generally rising Parisian market, with the CAC 40 up 0.75% at 8,013.77 points. Over the week, the stock has gained 10.13%, while its quarterly performance has reached 70.07%. However, it is the annual performance that is particularly impressive with an increase of 1,076%, more than ten times the performance of the CAC 40 over the same period. The biotechnology company continues to benefit from the momentum initiated by the announcement of positive preliminary results from the phase III clinical trials of its experimental drug Obefazimod for adults with moderate to severe ulcerative colitis. In early November, Abivax unveiled results from its phase 3 ABTECT induction trials evaluating Obefazimod, which demonstrate a significant improvement in the quality of life for patients with ulcerative colitis. These successive announcements have significantly enhanced the stock's valuation, now trading close to its resistance threshold at 98.70 euros. Regarding shareholding, two sales by executives totaling 1,181,754 shares for approximately 111.3 million euros were recorded, while Sofinnova Partners decreased below the 10% voting rights threshold in Abivax as a result of a share sale off and on the market on October 29. A net short position representing about 0.51% of the capital remains, indicating that some investors still anticipate a correction. On November 19, 2025, the company reported that its share capital amounted to 778,289.18 euros, divided into 77,885,595 shares as of October 31, 2025.
Technical Perspective
From a technical standpoint, the stock is significantly above its moving averages, confirming the strength of the upward trend. The 50-day moving average is at 79.90 euros, while the 200-day average is only at 35.05 euros, illustrating the magnitude of the recent rise. The growing gap between these two averages, which has increased from about 44.63 points to 44.84 points over the last twenty sessions, indicates a continuous acceleration of the movement. This configuration is generally interpreted as a signal for the continuation of the upward trend, especially as the stock is now touching the upper Bollinger band at 99.68 euros, close to the current level. The RSI (Relative Strength Index) stands at 58, a level that is in the neutral-bullish zone, far from the overbought thresholds at 70. This intermediate position suggests that the stock still has room for growth before entering overheated territory. Moreover, the MACD shows a line at 4.75 above its signal line at 4.07, with a positive histogram of 0.68, confirming the short-term bullish bias. The one-month volatility is at 16.46%, a high level but consistent for a biotech stock in advanced clinical development. The beta of 2.55, meanwhile, indicates a high sensitivity to market movements.
Market Trajectory and Future Prospects
Abivax's stock trajectory illustrates the unique challenges faced by clinical-stage biotechs, whose valuations are closely tied to the successes or failures of their therapeutic trials. The company plans to file a marketing authorization application with the FDA in the second half of 2026, subject to positive results from a 44-week maintenance trial, with preliminary data expected in the second quarter of 2026. These upcoming milestones remain potential catalysts for the stock. Analysts following the stock have varied price targets, but Stifel reiterates its buy recommendation on the stock and raises its price target to 100 euros (from 68 euros), exactly the level reached today. The technical support threshold is identified at 76.10 euros. With an ATR (Average True Range) of 2.68, the average daily fluctuations remain significant, confirming the need for investors to have a high tolerance for risk on this speculative stock.
